Skip to main content
PMC home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;95(5):459–463. doi: 10.1111/j.1349-7006.2004.tb03232.x

Late resistance to adenoviral p53‐mediated apoptosis caused by decreased expression of Coxsackie‐adenovirus receptors in human lung cancer cells

Yasuhisa Tango 1, Masaki Taki 2, Yoshiko Shirakiya 2, Shoichiro Ohtani 2, Naoyuki Tokunaga 2, Yosuke Tsunemitsu 2, Shunsuke Kagawa 2,3, Toru Tani 1, Noriaki Tanaka 2, Toshiyoshi Fujiwara 2,3,✉
PMCID: PMC11160061  PMID: 15132776

Abstract

Adenovirus‐mediated wild‐type p53 gene transfer induces apoptosis in a variety of human cancer cells. Although clinical trials have demonstrated that a replication‐deficient recombinant adenovirus expressing the wild‐type p53 gene (Ad‐p53) is effective in suppressing growth of non‐small cell lung cancer (NSCLC), we often experienced late resistance to this treatment. To elucidate the mechanism of late resistance to Ad‐p53 in human lung cancer cells, we generated 5 different resistant variants from p53‐susceptible H1299 NSCLC cells by repeated infections with Ad‐p53. We first examined the transduction efficiency of adenoviral vector by Ad‐LacZ transduction followed by X‐gal staining in parental and 5 resistant H1299 cell lines. Their sensitivity to viral infection decreased in correlation with the magnitude of resistance, and Ad‐p53‐mediated tumor suppression could be restored by dose escalation of Ad‐p53 in the resistant variants. The expression of Coxsackie and adenovirus receptor (CAR) and αV integrins, which are cellular receptors for attachment and internalization of the virus, respectively, was next investigated in these cell lines. Flow cytometry revealed that αVβ3 and αVβ5 integrin expression was consistent, while p53‐resistant cell lines showed that diminished CAR expression correlated with the magnitude of the resistance. Our results demonstrated that decreased CAR expression could be one of the mechanisms of late resistance to Ad‐p53, which may have a significant impact on the outcome of adenovirus‐based cancer gene therapy.

References

  • 1. Merritt JA, Roth JA, Logothetis CJ. Clinical evaluation of adenoviral‐mediated p53 gene transfer: review of INGN 201 studies. Semin Oncol 2001; 28: 105–14. [DOI] [PubMed] [Google Scholar]
  • 2. Svensson U, Oersson R, Everitt E. Virus‐receptor interaction in the adenovirus system I. Identification of virion attachment proteins of HeLa cell plasma membrane. J Virol 1981; 38: 70–81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Devaux C, Caillet‐Boudin ML, Jarcot B, Boulanger P. Crystallization, enzymatic cleavage, and the polarity of the adenovirus type 2 fiber. Virology 1987; 161: 121–8. [DOI] [PubMed] [Google Scholar]
  • 4. Greber UF, Willetts M, Webster P, Helenius A. Stepwise dismantling of adenovirus 2 during entry into cells. Cell 1993; 75: 477–86. [DOI] [PubMed] [Google Scholar]
  • 5. Louise N, Fender P, Barge A, Kitts P, Chroboczek J. Cell‐binding domain of adenovirus serotype 2 fiber. J Virol 1994; 68: 4104–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Bai M, Harfe B, Freimuth P. Mutations that alter an Arg‐Gly‐Asp (RGD) sequence in the adenovirus type 2 penton base protein abolish its cell‐rounding activity and delay virus reproduction in flat cells. J Virol 1993; 67: 5198–205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309–19. [DOI] [PubMed] [Google Scholar]
  • 8. Wickham TJ, Filardo EJ, Cheresh DA, Nemerow GR. Integrin alpha v beta 5 selectively promotes adenovirus mediated cell membrane permeabilization. J Cell Biol 1994; 127: 257–64. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Dechecchi MC, Tamanini A, Bonizzaato A, Cabrini G. Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2‐host cell interactions. Virology 2000; 268: 382–90. [DOI] [PubMed] [Google Scholar]
  • 10. Bergelson JM, Cunningham JA, Droguett G, Kurt‐Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320–3. [DOI] [PubMed] [Google Scholar]
  • 11. Bergelson JM, Krithivas A, Celli L, Droguett G, Horwitz MS, Wickham T, Crowell RL, Finberg RW. The murine CAR homolog is a receptor for cox‐sackie B virused and adenoviruses. J Virol 1998; 72: 415–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Maxwell SA, Davis GE. Biological and molecular characterization of an ECV‐304‐derived cell line resistant to p53‐mediated apoptosis. Apoptosis 2000; 5: 277–90. [DOI] [PubMed] [Google Scholar]
  • 13. Maxwell SA, Davis GE. Differential gene expression in p53‐mediated apoptosis‐resistant vs. apoptosis‐sensitive tumor cell lines. Proc Natl Acad Sci USA 2000; 97: 13009–14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Yamamoto S, Yoshida Y, Aoyagi M, Ohno K, Hirakawa K, Hamada H. Reduced transduction efficiency of adenoviral vectors expressing human p53 gene by repeated transduction into glioma cells in vitro. Clin Cancer Res 2002; 8: 913–21. [PubMed] [Google Scholar]
  • 15. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen‐Schaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus‐mediated transfer of the wild‐type p53 gene. Cancer Res 1994; 54: 2287–91. [PubMed] [Google Scholar]
  • 16. Zhang WW, Fang X, Mazur W, French BA, Georges RN, Roth JA. High‐efficacy gene transfer and high‐level expression of wild‐type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1994; 1: 5–13. [PubMed] [Google Scholar]
  • 17. Kagawa S, Fujiwara T, Hizuta A, Yasuda T, Zhang WW, Roth JA, Tanaka N. p53 expression overcome p21WAF1/ CIP1‐mediated G1 arrest and induces apoptosis in human cancer cells. Oncogene 1997; 15: 1903–9. [DOI] [PubMed] [Google Scholar]
  • 18. Fukazawa T, Fujiwara T, Morimoto Y, Shao J, Nishizaki M, Kadowaki Y, Hizuta A, Owen‐Schaub LB, Roth JA, Tanaka N. Differential involvement of the CD95 (Fas/APO‐1) receptor/ligand system in apoptosis induced by the wild‐type p53 gene transfer in human cancer cells. Oncogene 1999; 18: 2189–99. [DOI] [PubMed] [Google Scholar]
  • 19. El‐Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 812–25. [DOI] [PubMed] [Google Scholar]
  • 20. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk‐interacting protein Cip1 is a potent inhibitor of G1 cyclin‐dependent kinases. Cell 1993; 75: 805–16. [DOI] [PubMed] [Google Scholar]
  • 21. Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, Takei Y, Nakamura Y. A ribonucleotide reductase gene involved in a p53‐dependent cell‐cycle checkpoint for DNA damage. Nature 2000; 404: 24–5. [DOI] [PubMed] [Google Scholar]
  • 22. Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J 1993; 12: 461–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T, Tanaka N. Noxa, a BH3‐only member of the Bcl‐2 family and candidate mediator of p53‐induced apoptosis. Science 2000; 288: 1053–8. [DOI] [PubMed] [Google Scholar]
  • 24. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y, Taya Y. p53AIP1, a potent mediator of p53‐dependent apoptosis, and its regulation by Ser‐46‐phosphorylated p53. Cell 2000; 102: 849–62. [DOI] [PubMed] [Google Scholar]
  • 25. Thornborrow EC, Manfredi JJ. One mechanism for cell type‐specific regulation of the bax promoter by the tumor suppressor p53 is dictated by the p53 response element. J Biol Chem 1999; 274: 33747–56. [DOI] [PubMed] [Google Scholar]
  • 26. You Z, Fischer CD, Tong X, Hasenburg A, Aguilar‐Cordova E, Kieback GD. Coxsackie virus‐adenovirus receptor expression in ovarian cancer cell lines is associated with increased adenovirus transduction efficiency and transgene expression. Cancer Gene Ther 2001; 8: 168–75. [DOI] [PubMed] [Google Scholar]
  • 27. Mizuguchi H, Koizumi N, Hosono T, Ishii‐Watanabe A, Uchida E, Utoguchi N, Watanabe Y, Hayakawa T. CAR‐ or α v integrin‐binding ablated adenovirus vectors, but not fiber‐modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice. Gene Ther 2002; 9: 769–76. [DOI] [PubMed] [Google Scholar]
  • 28. Li Y, Pong RC, Bergelson JM, Hall MC, Sagalowsky AI, Tseng CP, Wang Z, Hsieh JT. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res 1999; 59: 325–30. [PubMed] [Google Scholar]
  • 29. Okegawa T, Li Y, Pong RC, Bergelson JM, Zhou J, Hsieh JT. The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. Cancer Res 2000; 60: 5031–6. [PubMed] [Google Scholar]
  • 30. Koizumi N, Mizuguchi H, Hosono T, Ishii‐Watanabe A, Uchida E, Utoguchi N, Watanabe Y, Hayakawa T. Efficient gene transfer by fiber‐mutant adenoviral vectors containing RGD peptide. Biochim Biophys Acta 2001; 1568: 13–20. [DOI] [PubMed] [Google Scholar]
  • 31. Wu H, Seki T, Dmitriev I, Uil T, Kashentseva E, Han T, Curiel DT. Double modification of adenovirus fiber with RGD and polylysine motif improves coxsackie virus‐adenovirus receptor‐independent gene transfer efficiency. Hum Gene Ther 2002; 13: 1647–53. [DOI] [PubMed] [Google Scholar]
  • 32. Kawashima T, Kagawa S, Kobayashi N, Shirakiya Y, Umeoka T, Teraishi F, Taki M, Kyo S, Tanaka N, Fujiwara T. Telomerase‐specific replication‐selective virotherapy for human cancer. Clin Cancer Res 2004; 10: 285–92. [DOI] [PubMed] [Google Scholar]
  • 33. Mizuguchi H, Hayakawa T. Adenovirus vectors containing chimeric type 5 and type 35 fiber proteins exhibit altered and expanded tropism and increase the size limit of foreign genes. Gene 2002; 285: 69–77. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES